Compare PDFS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | SUPN |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2000 | 2010 |
| Metric | PDFS | SUPN |
|---|---|---|
| Price | $54.04 | $42.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $61.50 | ★ $61.75 |
| AVG Volume (30 Days) | 526.4K | ★ 583.8K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $20.46 | $23.21 |
| Revenue Next Year | $20.66 | $54.85 |
| P/E Ratio | $247.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.55 | $40.51 |
| 52 Week High | $71.69 | $59.68 |
| Indicator | PDFS | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 44.69 |
| Support Level | $49.15 | $40.51 |
| Resistance Level | $56.46 | $52.33 |
| Average True Range (ATR) | 1.95 | 1.35 |
| MACD | 0.40 | 0.05 |
| Stochastic Oscillator | 72.14 | 32.02 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.